Retatrutide's first phase 3 diabetes trial lands, weight loss included

Retatrutide, the triple GIP, GLP-1 and glucagon receptor agonist that produced the largest weight losses of any incretin drug in obesity, now has its first published phase 3 result in type 2 diabetes: in TRANSCEND-T2D-1, the highest dose lowered glycated haemoglobin (HbA1c) by 1.12 percentage points more than placebo and cut bodyweight by 15.3% over 40 weeks [s1]. The trial was designed around glucose, not weight — HbA1c was the primary endpoint — but the weight numbers are the ones that will draw attention.

What the trial did

TRANSCEND-T2D-1 was a 40-week, phase 3, randomised, double-blind, placebo-controlled trial run at 48 sites in the USA, Mexico and India [s1]. It enrolled adults with type 2 diabetes inadequately controlled by diet and exercise alone — no background glucose-lowering drugs — with HbA1c between 7.0% and 9.5% (53–80 mmol/mol) and a BMI of at least 23 kg/m² [s1]. Between 10 April 2024 and 21 April 2025, 930 people were screened and 537 randomly assigned in a 1:1:1:1 ratio to once-weekly subcutaneous retatrutide 4 mg (n=134), 9 mg (n=133), 12 mg (n=136), or placebo (n=134) [s1]. Of those, 296 (55%) were female and 241 (45%) male [s1].

This was an early, drug-naive population: baseline mean age was 48.8 years (SD 12.1), mean HbA1c 7.9% (SD 1.1), mean diabetes duration just 2.5 years (SD 4.4), and mean BMI 35.8 kg/m² (SD 7.0) [s1]. Completion was high — 490 participants (91%) finished the treatment period on study drug and 504 (94%) completed the study [s1]. The trial was funded by Eli Lilly and Company, and is registered as NCT06354660 [s1].

The numbers

The primary analysis used the treatment-regimen estimand, which counts data from every randomised participant regardless of whether they stopped the drug — the more conservative of the two standard analyses. Under it, HbA1c fell by 1.69% (SE 0.11) on 4 mg, 1.86% (0.10) on 9 mg and 1.94% (0.08) on 12 mg, against 0.81% (0.12) on placebo [s1]. The estimated treatment differences versus placebo were −0.88 percentage points (95% CI −1.18 to −0.59) at 4 mg, −1.04 (−1.32 to −0.76) at 9 mg and −1.12 (−1.39 to −0.85) at 12 mg, all with p<0.0001 [s1].

Weight, a key secondary endpoint, moved further. Mean bodyweight change at 40 weeks was −11.5% (SE 0.7) on 4 mg, −13.9% (0.8) on 9 mg and −15.3% (0.8) on 12 mg, versus −2.6% (0.5) on placebo [s1]. That places the top dose's 40-week weight loss in the range incretin drugs usually reach only in obesity trials that run to 72 weeks and enrol people without diabetes — a group in which these agents consistently produce larger weight effects.

What it does and does not settle

The direction is not new. An earlier phase 2 trial had already shown retatrutide producing dose-dependent reductions in both HbA1c and bodyweight in type 2 diabetes, which is what pushed the drug into phase 3 [s2]. TRANSCEND-T2D-1 confirms that signal at scale, in a defined early-diabetes population, with a conservative primary analysis [s1].

What it cannot tell you is how retatrutide compares against the drugs a newly diagnosed patient would actually be offered. There was no active comparator — the control arm received placebo, not metformin, a GLP-1 agonist or tirzepatide [s1]. The population was also unusually favourable: short diabetes duration, no background therapy, and a mean HbA1c under 8% leave more room to move than a typical clinic caseload. And 40 weeks is short. Durability, and whether the weight and glucose effects hold once a patient adds other medications or stops the drug, are not addressed here.

Safety, as far as it goes

The adverse-event profile was the familiar one for this class: mostly mild-to-moderate gastrointestinal effects that subsided over time [s1]. Discontinuations due to adverse events ran at 2–5% across the retatrutide groups versus 0% on placebo, and no severe hypoglycaemia was reported [s1]. Two deaths occurred during the study, both in the retatrutide 4 mg group and both judged unrelated to the study drug [s1].

Neither this trial nor its phase 2 predecessor was designed to measure cardiovascular events, and neither reports them as an endpoint [s1][s2]. Both were funded by the manufacturer [s1][s2]. Lilly frames retatrutide as a potential treatment for diabetes, obesity and related complications [s1]; that framing is the company's, and it rests, for now, on surrogate markers — HbA1c and weight — rather than on hard outcomes. The larger phase 3 programme, including dedicated obesity and cardiovascular-outcome trials, is what will decide where the drug sits.

This article is informational and does not constitute medical advice.